Results 21 to 30 of about 1,906,742 (351)

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Journal of Hematology & Oncology, 2018
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
Guoshuang Shen, F. Zheng, Dengfeng Ren, F. Du, Qiuxia Dong, Ziyi Wang, F. Zhao, Raees Ahmad, Jiuda Zhao   +8 more
semanticscholar   +1 more source

The nucleotide and partial amino acid sequences of rat fetuin [PDF]

, 1992
Fetuins are among the major plasma proteins, yet their biological role has remained elusive. Here we report the molecular cloning of rat fetuin and the sequence analysis of a full-length clone, RF619 of 1456 bp with an open reading frame of 1056 bp ...
Albrecht G. J., Brown W. M., Cam A., Cayatte A. J., Christie D. L., Cohen P., Colclasure G. C., Coughlin J. P., Davis L. G., Dziegielewska K. M., Dziegielewska K. M., Dziegielewska K. M., Edge A. S. B., Haasemann M., Heijne G., Hortin G., Jones S. E., Kellermann J., Laemmli U. K., Lee C. C., Lewis J. G., Mizuno M., Mollgard K., Muller-Esterl W., Oss C. J., Pedersen K. O., Puck T. T., Rawlings N. D., Rohrlich S. T., Sambrook J., Sanger F., Sbraccia P., Schultze H. E., Strauss E. C., Triffitt J. T., Yang F., Yet M. G.   +36 more
core   +1 more source

Role of Bruton’s tyrosine kinase in B cells and malignancies

Molecular Cancer, 2018
Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary
Simar Pal Singh, Floris Dammeijer, R. Hendriks   +2 more
semanticscholar   +1 more source

Interactions between Two Cytoskeleton-associated Tyrosine Kinases: Calcium-dependent Tyrosine Kinase and Focal Adhesion Tyrosine Kinase [PDF]

Journal of Biological Chemistry, 1999
The calcium-dependent tyrosine kinase (CADTK), also known as Pyk2/RAFTK/CAKbeta/FAK2, is a cytoskeleton-associated tyrosine kinase. We compared CADTK regulation with that of the highly homologous focal adhesion tyrosine kinase (FAK). First, we generated site-specific CADTK mutants.
X, Li, R C, Dy, W G, Cance, L M, Graves, H S, Earp   +4 more
openaire   +2 more sources

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Targeting kinases with anilinopyrimidines: Discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily [PDF]

, 2015
Kinase inhibitors are attractive drugs/drug candidates for the treatment of cancer. The most recent literature has highlighted the importance of multi target kinase inhibitors, although a correct balance between specificity and non-specificity is ...
Chilin, Adriana, DALLA VIA, Martina, Ferrarese, Alessandro, Gandin, Valentina, Marzano, Cristina, Marzaro, Giovanni   +5 more
core   +2 more sources

Receptor Tyrosine Kinase-Mediated Angiogenesis [PDF]

Cold Spring Harbor Perspectives in Biology, 2013
The endothelial cell is the essential cell type forming the inner layer of the vasculature. Two families of receptor tyrosine kinases (RTKs) are almost completely endothelial cell specific: the vascular endothelial growth factor (VEGF) receptors (VEGFR1-3) and the Tie receptors (Tie1 and Tie2). Both are key players governing the generation of blood and
Alitalo Kari, Jeltsch Michael, Saharinen Pipsa, Leppänen Veli-Matti, Alitalo Kari, Jeltsch Michael, Saharinen Pipsa, Leppänen Veli-Matti   +7 more
openaire   +2 more sources

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion [PDF]

, 2014
This article has been made available through the Brunel Open Access Publishing Fund.PTK6/Brk is a non-receptor tyrosine kinase overexpressed in cancer.
Blokland, NJG, Broos, AWT, Eccles, SA, Hammond, EM, Harvey, AJ, Pires, IM, Poujade, F-A, Senra, JM, Span, PN   +8 more
core   +4 more sources

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

Journal of Biological Chemistry, 1996
Here, we have studied the activity of a novel protein-tyrosine kinase inhibitor that is selective for the Src family of tyrosine kinases. We have focused our study on the effects of this compound on T cell receptor-induced T cell activation, a process ...
J. Hanke, J. Gardner, R. L. Dow, P. Changelian, W. Brissette, E. J. Weringer, B. Pollok, P. Connelly   +7 more
semanticscholar   +1 more source